low molecular weight heparin


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to low molecular weight heparin: Enoxaparin

low mo·lec·u·lar weight hep·a·rin

(LMWH) (lō mŏ-lek'yŭ-lăr wāt hep'ăr-in)
A form of heparin with a longer half life and fewer adverse effects (e.g., thrombocytopenia).

low molecular weight heparin

Abbreviation: LMWH
The most bioavailable fraction of heparin. It has a more precise anticoagulant effect than unfractionated heparins and is used to prevent and treat deep venous thrombosis, pulmonary embolism, and acute coronary syndromes.

CAUTION!

It should be used selectively, if at all, in patients with reduced kidney function.
See also: heparin
References in periodicals archive ?
Key Takeaways of the Low Molecular Weight Heparin Market:*The global low molecular weight heparin market is expected to witness a CAGR of 6.7% during the forecast period (2018 - 2026), owing to increasing research and development activities in LMWH, globally *Among drugs, the enoxaparin segment accounted for major market share in 2017.
Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
Zhai, "Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin," International Journal of Pharmaceutics, vol.
Caption: Figure 5: Effects of low molecular weight heparin nebulization on GSH-Px activity.
Low molecular weight heparins have been used to reduce thromboembolic risk in both primary care and the hospital setting for at least twenty years (Clagett et al 1995, Imberti et al 2006, Mohr et al 1993, Wolf 1994).
This test may not be performed by all labs, but may be available at labs with a blood bank or those currently testing anti-Xa levels for other low molecular weight heparins. The plasma anti-Xa level should be drawn prior to the dose administration for the second dialysis treatment and then pretreatment for each subsequent dialysis treatment.
Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials.
President and CEO of PolyMedix Nicholas Landekic said that in previous studies PMX-60056 had met the safety and efficacy endpoints in reversing the anticoagulant activity of unfractionated heparin and the low molecular weight heparin, tinzaparin.
Enoxaparin is a low molecular weight heparin (LWMH) commonly used in clinics with few untoward effects pertaining to bleeding or hematoma.
Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
Over the past few years, clinical studies have revealed the benefits of a smaller heparin molecule - low molecular weight heparin (LMWH) - which impedes coagulation differently than so-called standard heparin (more properly designated as unfractionated heparin).
Low molecular weight heparin (LMW heparin) can be called a "leaner" and more efficient form of the standard heparin compound.

Full browser ?